Rosetta Genomics (ROSG) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Rosetta Genomics Reports 2016 Second Quarter Financial Results
September 26, 2016 4:05 PM EDTRosettaGX Reveal for the Diagnosis of Indeterminate Thyroid FNA Expected to Drive Significant Revenue Growth over the Next Several Years
Conference call begins today at 4:30 p.m. Eastern time
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, reports financial results for the three and six months ended June 30, 2016.
Recent developments include:
Gross billings for RosettaGX Reveal (Reveal), the Companys first-of-its-kind microRNA classifier for indeterminate thyroid nodules, are tracking to be... More